SFDA Expands Lojuxta Indication to Include Treatment of Children with Homozygous Familial Hypercholesterolemia
Riyadh: The Saudi Food and Drug Authority (SFDA) announced its approval of a new medical claim for Lojuxta (lomitapide), allowing its use to treat children aged five years and older diagnosed with Homozygous Familial Hypercholesterolemia (HoFH). This …